Burgdorf - Ypsomed filed a lawsuit against Sanofi-Aventis in Germany. Ypsomed believes that the SoloStar injection system developed and manufactured by Sanofi-Aventis is in breach of its own patents. Sanofi-Aventis uses the SoloStar pen for administration of its Lantus and Apidra insulin products. Ypsomed is seeking a ban on the manufacture and supply of the Sanofi-Aventis SoloStar pen and is applying for compensation. Ypsomed invests more than CHF 25 million annually in research and development and actively protects its patented products and technology. Ypsomed currently has supply contracts with Sanofi-Aventis, which means that Sanofi-Aventis continues to be an important customer for the OptiSet, OptiClik and OptiPen Pro products.
Press Releases Ypsomed Group